Siemens companions with Miko Pharma to develop cutting-edge pharmaceutical manufacturing amenities in Ghana.
The settlement goals to create 130 jobs and produce inexpensive, high-quality drugs for varied illnesses.
Ghana’s pharmaceutical sector is ready for vital growth, with gross sales forecasted to achieve GH₵10.7 billion by 2028.
Siemens (www.Siemens.com), the trusted international know-how chief, has signed a landmark settlement with Miko Pharma to develop state-of-the-art amenities for the native manufacturing of life-saving generic prescribed drugs in Ghana. This deal, one of many largest in Ghanaian pharmaceutical historical past, was finalized on the prestigious Hannover Messe commerce present in Germany.
Siemens might be accountable for creating industrial functions, buildings, infrastructure, and utilities for Miko Pharma’s operations in Japanese Ghana, adhering to stringent World Well being Group requirements.
“Our aim is to allow the manufacture of protected pharmaceutical medication in Africa. This partnership with Miko Pharma represents a big step in direction of attaining that aim. By leveraging our cutting-edge know-how and unparalleled experience, we goal to create a sustainable and self-sufficient pharmaceutical trade in Ghana. We’re honoured to assist our companions on this transformative journey,” says Sabine Dall’Omo, CEO, Siemens Sub-Saharan Africa.
“Miko Pharma plans to create 130 jobs within the manufacturing of inexpensive and efficient superior high quality drugs for the remedy of varied illnesses, together with hypertension, diabetes, coronary heart illness, HIV, malaria, and ache, in Ghana,” based on Dr Michael Obeng, CEO and founding father of Miko Pharma, a Harvard-trained plastic and reconstructive surgeon and a fellow of the American Faculty of Surgeons. “This initiative will considerably improve healthcare accessibility within the area.”
“Being in Germany to signal this historic settlement with Siemens was a second of immense delight for our staff at Miko Pharma. This partnership is not only about constructing amenities—it’s about reworking healthcare in Ghana and setting a brand new normal for pharmaceutical manufacturing in Africa. With Siemens’ experience, we’re assured that these state-of-the-art amenities will ship inexpensive, high-quality drugs to those that want them most, whereas additionally creating significant employment alternatives. This can be a pivotal step towards our imaginative and prescient of a self-reliant and thriving pharmaceutical sector in Ghana,” says Mr Willard Jackson, Govt Director for Miko Pharma.
This historic settlement between Siemens and Miko Pharma marks a big milestone in Ghana’s pharmaceutical trade, promising substantial financial progress and improved healthcare accessibility. By leveraging world-class know-how and experience, this partnership goals to empower native manufacturing and create a sustainable future for pharmaceutical manufacturing in Ghana.
Overview of the pharmaceutical trade in Ghana
Presently, 30% of pharmaceutical demand in Ghana is met by regionally produced merchandise.
The Ghana Meals and Medicine Authority recorded 36 pharmaceutical manufacturing amenities with energetic licenses and over 3500 pharmaceutical outlets by 2023.
The pharmaceutical trade is a rising contributor to the Ghanaian financial system, accounting for 0.8% of GDP and 21.8% of complete healthcare expenditure in 2023. Analysis by Deloitte Ghana signifies that pharmaceutical gross sales in Ghana reached GHS6.6bn (US$571mn) in 2023 and are forecasted to develop to GH₵10.7 billion (US$735mn) by 2028, pushed by elevated consumption inside the generic medicines sub-sector. Statista initiatives that the pharmaceutical market in Ghana will obtain a income of US$254.88m in 2025.
The Siemens-Miko Pharma deal has the potential to considerably enhance the native pharmaceutical manufacturing trade, surpassing earlier financial forecasts.
Distributed by APO Group on behalf of Siemens AG.
About Siemens:
Siemens AG (Berlin and Munich) is a number one know-how firm targeted on trade, infrastructure, mobility, and healthcare. The corporate’s function is to create know-how to rework the on a regular basis, for everybody. By combining the true and the digital worlds, Siemens empowers prospects to speed up their digital and sustainability transformations, making factories extra environment friendly, cities extra livable, and transportation extra sustainable. Siemens additionally owns a majority stake within the publicly listed firm Siemens Healthineers, a number one international medical know-how supplier pioneering breakthroughs in healthcare. For everybody. All over the place. Sustainably.
In fiscal 2024, which ended on September 30, 2024, the Siemens Group generated income of €75.9 billion and internet earnings of €9.0 billion. As of September 30, 2024, the corporate employed round 312,000 folks worldwide on the premise of continuous operations. Additional info is offered on the Web at www.Siemens.com.
